218 related articles for article (PubMed ID: 9916110)
1. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice.
Hu MS; Schwartzman JD; Yeaman GR; Collins J; Seguin R; Khan IA; Kasper LH
Infect Immun; 1999 Feb; 67(2):928-35. PubMed ID: 9916110
[TBL] [Abstract][Full Text] [Related]
2. Involvement of apoptosis and interferon-gamma in murine toxoplasmosis.
Shen DF; Matteson DM; Tuaillon N; Suedekum BK; Buggage RR; Chan CC
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2031-6. PubMed ID: 11481268
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand (gld)- and Fas (lpr)-deficient mice do not show alterations in the extravasation or apoptosis of inflammatory neutrophils.
Fecho K; Cohen PL
J Leukoc Biol; 1998 Sep; 64(3):373-83. PubMed ID: 9738665
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells.
Rich RF; Green WR
J Virol; 1999 May; 73(5):3826-34. PubMed ID: 10196277
[TBL] [Abstract][Full Text] [Related]
5. Experimental ocular toxoplasmosis induced in naive and preinfected mice by intracameral inoculation.
Hu MS; Schwartzman JD; Lepage AC; Khan IA; Kasper LH
Ocul Immunol Inflamm; 1999 Mar; 7(1):17-26. PubMed ID: 10410871
[TBL] [Abstract][Full Text] [Related]
6. Crucial Fas-Fas ligand interaction in spontaneous acceptance of hepatic allografts in mice.
Uchiyama H; Kishihara K; Minagawa R; Hashimoto K; Sugimachi K; Nomoto K
Immunology; 2002 Apr; 105(4):450-7. PubMed ID: 11985665
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.
Kim S; Kim KA; Hwang DY; Lee TH; Kayagaki N; Yagita H; Lee MS
J Immunol; 2000 Mar; 164(6):2931-6. PubMed ID: 10706679
[TBL] [Abstract][Full Text] [Related]
8. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis.
Wahlsten JL; Gitchell HL; Chan CC; Wiggert B; Caspi RR
J Immunol; 2000 Nov; 165(10):5480-6. PubMed ID: 11067900
[TBL] [Abstract][Full Text] [Related]
9. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.
Fleck M; Zhang HG; Kern ER; Hsu HC; Müller-Ladner U; Mountz JD
Arthritis Rheum; 2001 Apr; 44(4):964-73. PubMed ID: 11315936
[TBL] [Abstract][Full Text] [Related]
11. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
Djamali A; Odorico JS
Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand is required for resolution of granulomatous experimental autoimmune thyroiditis.
Wei Y; Chen K; Sharp GC; Braley-Mullen H
J Immunol; 2004 Dec; 173(12):7615-21. PubMed ID: 15585889
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T cells in the pathogenesis of murine ocular toxoplasmosis.
Lu F; Huang S; Kasper LH
Infect Immun; 2004 Sep; 72(9):4966-72. PubMed ID: 15321988
[TBL] [Abstract][Full Text] [Related]
14. Mice deficient in fas ligand (gld) or fas (lpr) show few alterations in granulopoiesis.
Fecho K; Bentley SA; Cohen PL
Cell Immunol; 1998 Aug; 188(1):19-32. PubMed ID: 9743554
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells.
Shimizu M; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
Cancer Immunol Immunother; 1998 Nov; 47(3):143-8. PubMed ID: 9829839
[TBL] [Abstract][Full Text] [Related]
16. T cell receptor ligation triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent.
Davidson WF; Haudenschild C; Kwon J; Williams MS
J Immunol; 2002 Dec; 169(11):6218-30. PubMed ID: 12444127
[TBL] [Abstract][Full Text] [Related]
17. The role of Fas-FasL in the development and treatment of ischemic retinopathy.
Barreiro R; Schadlu R; Herndon J; Kaplan HJ; Ferguson TA
Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):1282-6. PubMed ID: 12601060
[TBL] [Abstract][Full Text] [Related]
18. FasL-Fas interactions regulate neovascularization in the cornea.
Stuart PM; Pan F; Plambeck S; Ferguson TA
Invest Ophthalmol Vis Sci; 2003 Jan; 44(1):93-8. PubMed ID: 12506060
[TBL] [Abstract][Full Text] [Related]
19. The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.
Priceputu E; Rodrigue I; Chrobak P; Poudrier J; Mak TW; Hanna Z; Hu C; Kay DG; Jolicoeur P
J Virol; 2005 May; 79(10):6377-91. PubMed ID: 15858021
[TBL] [Abstract][Full Text] [Related]
20. Fas Ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver.
Lombard C; McKallip RJ; Hylemon PB; Nagarkatti PS; Nagarkatti M
Clin Immunol; 2003 Nov; 109(2):144-53. PubMed ID: 14597213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
